<DOC>
	<DOCNO>NCT02453555</DOCNO>
	<brief_summary>This trial compare use fiixed dose conbination empagliflozin linagliptin linagliptine alone patient type 2 diabetes mellitus</brief_summary>
	<brief_title>Empagliflozin Add Linagliptin Study Japanese Patient With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis T2DM prior inform consent 2 . Male female patient diet exercise regimen least 12 week prior inform consent : 1 drugnaïve , define antidiabetic drug least 12 week prior inform consent , 2 pretreated one oral antidiabetic drug ( sulfonylurea , half maximum approve dose ) stable dosage least 12 week prior inform consent ( thiazolidinedione , therapy unchanged least 18 week prior inform consent , linagliptin 5 mg least 16 week prior Visit 1 ) . Individual antidiabetic drug ( except linagliptin ) discontinue Visit 1 . 3 . HbA1c Visit 1 1 HbA1c =8.0 % =10.5 % patient drugnaïve , 2 HbA1c =7.5 % =10.5 % patient one oral antidiabetic drug ( except linagliptin ) , 3 HbA1c =7.5 % =10.0 % patient linagliptin 5 mg 4 . HbA1c =7.5 % =10.0 % Visit 4 randomisation doubleblind treatment period . Patient pretreated linagliptin 5 mg 16 week prior Visit 1 meet criterion HbA1c directly move runin ( Visit 4 ) . 5 . Age =20 year inform consent 6 . BMI =40.0 kg/m2 Visit 1 ( screen ) 7 . Signed date write informed consent date Visit 1 accordance Good Clinical Practice ( GCP ) local legislation Exclusion criterion : 1 . Uncontrolled hyperglycemia glucose level &gt; 270 mg/dL ( &gt; 15.0 mmol/L ) overnight fast openlabel stabilisation period ( Visit 2 Visit 4 ) runin period ( Visit 4 Visit 5 ) , confirm second measurement ( day do either central local laboratory ) . 2 . Acute coronary syndrome ( STelevation myocardial infarction [ STEMI ] , nonSTEMI , unstable angina pectoris ) , stroke transient ischemic attack within 12 week prior inform consent 3 . Indication liver disease , define serum level either alanine aminotransferase ( ALT [ SGPT ] ) , aspartate aminotransferase ( AST [ SGOT ] ) , alkaline phosphatase ( ALP ) 3 x upper limit normal ( ULN ) determine screening , openlabel stabilisation period and/or runin period 4 . Impaired renal function , define estimate glomerular filtration rate ( eGFR ) &lt; 45 mL/min/1.73 m2 ( MDRD formula ) determine screening , openlabel stabilisation period and/or runin period 5 . Known hereditary galactose intolerance 6 . Known contraindication linagliptin empagliflozin accord Japanese label 7 . Any previous ( within 2 year prior inform consent ) plan bariatric surgery ( weight loss surgery ) gastrointestinal surgery induce chronic malabsorption 8 . Medical history cancer ( except resect noninvasive basal cell squamous carcinoma ) and/or treatment cancer within last 5 year 9 . Known blood dyscrasia disorder cause haemolysis unstable red blood cell ( RBC ) count ( e.g . malaria , babesiosis , haemolytic anaemia ) . 10 . Treatment insulin , GLP1 agonists , within 12 week prior inform consent 11 . Treatment antiobesity drug within 12 week prior informed consent treatment time screen ( i.e. , surgery , aggressive diet regimen , etc . ) lead unstable body weight 12 . Current treatment systemic steroid ( inhaled topical steroid ) inform consent change dosage thyroid hormone within 6 week prior inform consent uncontrolled endocrine disorder except T2DM 13 . Premenopausal woman ( last menstruation =1 year prior informed consent ) : 1 nursing pregnant 2 childbearing potential practicing acceptable method birth control , plan continue use method throughout trial agree submit periodic pregnancy test participation trial . Acceptable method birth control include tubal ligation , intra uterine devices/systems , oral contraceptive , complete sexual abstinence , double barrier method vasectomise partner 14 . Known suspected allergy hypersensitivity trial product relate product ( e.g. , DPP4 inhibitor SGLT2 inhibitor ) 15 . Alcohol drug abuse within 12 week prior inform consent would interfere trial participation ongoing condition lead decrease compliance trial procedure trial drug intake , judgment investigator 16 . Intake investigational drug another trial within 30 day prior Visit 1 participation followup period another trial ( participation observational study permit ) 17 . Any clinical condition , opinion investigator , would jeopardize patient¿s safety participate clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>